Elixinol Wellness
- Short interest
- 0.04%
- 0.00 pp 30d
- as of 28 June 2023
- Reported shorts
- 190.9K
- Shares on issue
- 456.991M
Elixinol Wellness (EXL) financials
Results, ratios and statements
Latest result
Half year to 30 Jun 2026 (HY26), figures in AUD, the reporting currency · Company filing, 31 Aug 2026
- Revenue
- $7.8MF (source: Company filing (extracted))vs n/a
- Company filing (extracted), as at 11 Oct 2026
- NPAT
- −$1.1MF (source: Company filing (extracted))vs n/a
- Company filing (extracted), as at 11 Oct 2026
- EPS (basic)
- n/avs n/a
- Rev YoY
- +3.6%FY
- EPS YoY
- n/aTTM
- Company filing (extracted)
Summary of EXL Appendix 4D and Half-year Financial Report, 31 Aug 2026
Elixinol Wellness reported a 2.2% revenue increase to $7.8 million for the half-year ended 30 June 2026, while its net loss narrowed by 65.4% to $1.1 million. No dividend was declared. The company highlighted improved gross margins and cost reductions, but noted a material uncertainty regarding going concern and is pursuing a US business divestment and additional funding.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 31 Dec 2025 (FY); balance sheet at 31 Dec 2025; prices to 15 Oct 2026
- Gross margin
- 38.7%
- Operating margin
- −38.6%
- Net margin
- −35.5%
- FCF margin
- −21.4%
- ROE
- −62.9%
- ROA
- −32.0%
- FCF conversion
- n/a
- Net debt (excl. leases)
- $2.0M
- Net debt / EBITDA
- n/a
- Current ratio
- 0.9×
- Interest cover
- −14.4×
- Cash dividends paid / net profit
- n/a
- Market cap
- n/a (listed unit is not one ordinary share)
- P/E
- n/a (listed unit is not one ordinary share)
- P/B
- n/a (listed unit is not one ordinary share)
Ratios use the reporting currency (AUD); market cap is in AUD. Source: Yahoo Finance, as at 14 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Revenue | $15.5M | $15.0M | $8.5MM (source: ASX (Markit)) | $7.1M |
| Gross profit | $6.0M | $5.6M | n/a | $3.2M |
| Operating income | −$6.0M | −$5.1M | n/a | −$10.0M |
| EBITDA | −$4.8M | −$4.1M | n/a | −$9.3M |
| EBIT | −$5.6M | −$5.1M | n/a | −$10.0M |
| Interest expense | $416.0K | $177.0K | n/a | n/a |
| Pretax income | −$6.0M | −$5.3M | n/a | −$10.6M |
| Tax | −$535.0K | −$3.6M | n/a | $2.0K |
| NPAT | −$5.5M | −$1.7M | −$7.5MM (source: ASX (Markit)) | −$10.6M |
| Net interest income | −$481.0K | −$182.0K | n/a | −$49.0K |
| EPS basic | −$0.021 | −$0.011 | −$0.099 | −$0.21 |
| EPS diluted | −$0.021 | −$0.011 | −$0.099 | −$0.21 |
| Shares | 414.0M | 220.8M | 632.7M | 316.1M |
- ASX (Markit)
Financial reports
The company's own filings, newest first
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report14 Oct 2026via asx_announcements
- EXL Appendix 4D and Half-year Financial ReportHalf Year Results31 Aug 2026via asx_announcements
Figures above come from this filing
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report28 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report21 Apr 2026via asx_announcements
- FY25 Appendix 4E and Annual ReportAnnual Results27 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Jan 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Oct 2025via asx_announcements
- H1 FY2025 Results - Appendix 4DHalf Year Results29 Aug 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Jul 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Apr 2025via asx_announcements
Showing 10 of 20 reports